Hirtle Callaghan & Co’s Novo Nordisk NVO Stock Holding History

Hirtle Callaghan & Co’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$715K	Hold	19,457	–	–	0.02%	72
2025 Q4	$990K	Hold	19,457	–	–	0.03%	66
2025 Q3	$1.08M	Hold	19,457	–	–	0.04%	60
2025 Q2	$1.34M	Buy	19,457 +896	+5%	+$60.9K	0.05%	57
2025 Q1	$1.29M	Buy	+18,561	New	+$1.53M	0.05%	59
2015 Q1	–	Sell	-39,780	Closed	-$842K	–	261
2014 Q4	$842K	Sell	39,780 -2,800	-7%	-$62.5K	0.2%	78
2014 Q3	$1.01M	Sell	42,580 -1,220	-3%	-$28.1K	0.17%	66
2014 Q2	$1.01M	Hold	43,800	–	–	0.14%	94
2014 Q1	$1.01M	Sell	43,800 -1,450	-3%	-$30.9K	0.17%	77
2013 Q4	$836K	Hold	45,250	–	–	0.11%	96
2013 Q3	$766K	Buy	+45,250	New	+$761K	0.12%	99

Other funds holding NVO

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Hirtle Callaghan & Co's NVO Position: Q1 2026 in Review

Hirtle Callaghan & Co held its Novo Nordisk (NVO) position steady in Q1 2026 at 19,457 shares worth $715K. The position accounts for 0.02% of the portfolio, ranked #72.

Hirtle Callaghan & Co first reported a position in NVO in Q3 2013 and has held it in 11 quarters since. The position peaked at $1.34M in Q2 2025. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

Hirtle Callaghan & Co held 19,457 shares of Novo Nordisk worth $715K as of Q1 2026.
Hirtle Callaghan & Co left its Novo Nordisk share count unchanged in Q1 2026.
Novo Nordisk made up 0.02% of Hirtle Callaghan & Co's portfolio in Q1 2026, its #72 holding.
Hirtle Callaghan & Co first reported a position in Novo Nordisk in Q3 2013 and has held it in 11 quarters since.
Hirtle Callaghan & Co's Novo Nordisk position peaked at $1.34M in Q2 2025.
1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2026, filed 13 May 2026.